The GastroIntestinal Research Foundation Launches New Multi-Million Dollar Funding Initiative Aimed at Curing Cancers of the Digestive System
November 03, 2022 13:00 ET | GastroIntestinal Research Foundation
CHICAGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Despite centuries of research, treating and curing cancer remains an urgent health research priority. With generous support from anonymous donors, the...
COMBINEDBrain Received the Global Genes 2022 Health Equity RARE Patient Impact Grant
September 29, 2022 11:27 ET | COMBINEDBrain Inc
NASHVILLE, Tenn., Sept. 29, 2022 (GLOBE NEWSWIRE) -- COMBINEDBrain (Consortium for Outcome Measures and Biomarkers for Neurodevelopmental Disorders), a non-profit organization of patient advocacy...
Throne Biotechnologies Wins '5 Best BioTech Companies To Watch' Award From The Silicon Review
March 28, 2022 09:00 ET | Throne Biotechnologies Inc
PARAMUS, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- Throne Biotechnologies (Throne), one of the global-leading biotech companies aiming to find a cure for type 1 diabetes and other autoimmune...
ibn-iw-globe-2.png
IBN (InvestorBrandNetwork) Announces Latest Episode of The Bell2Bell Podcast Featuring Matt Stang, CEO of Delic Holdings Corp.
November 16, 2021 08:17 ET | InvestorBrandNetwork (IBN)
NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- IBN (InvestorBrandNetwork), a multifaceted communications organization engaged in connecting public companies to the investment...
Exavir Therapeutics announces preclinical data demonstrating complete elimination of HIV from human cells with LNP-delivered Tat-targeted CRISPR-Cas9
November 10, 2021 07:30 ET | Exavir Therapeutics
Early candidate from XVIR-TAT series demonstrated genetic elimination of HIV and robust anti-retroviral activity with CRISPR-Cas9 based excision Exavir lipid nanoparticles (LNPs) with mRNA...
Exavir Therapeutics announces publication of preclinical data for novel tenofovir prodrug, XVIR-210, in Nature Communications, demonstrating long-acting exposures sufficient for antiviral activity against HIV and HBV
September 16, 2021 07:30 ET | Exavir Therapeutics
With a single administration, XVIR-210, a nano-formulated prodrug of tenofovir, provided drug levels sufficient for chronic HBV treatment, HIV treatment, and HIV prophylaxis for over two months in...
Exavir Therapeutics announces the publication of preclinical data for the ultra-long-acting integrase inhibitor XVIR-110 in Nature Communications, affirming its unique pharmacokinetic profile and potential as a best-in-class yearly antiretroviral
June 08, 2021 07:00 ET | Exavir Therapeutics
With a single administration, XVIR-110, a nano-formulated prodrug integrase inhibitor, provided year-long plasma drug levels sufficient for HIV treatment and prophylaxis in animal models Studies...
logo-dark.png
Aegis Sciences Announces CDC Contract to Provide Genomic Sequencing of SARS-CoV-2 to Aid Public Health Response to COVID-19
March 16, 2021 09:00 ET | Aegis Sciences Corporation
NASHVILLE, Tenn., March 16, 2021 (GLOBE NEWSWIRE) -- Aegis Sciences Corporation, a leading healthcare company that provides clinically innovative COVID-19 and medication compliance testing services,...
logo-dark.png
Aegis Sciences Corporation announces it has been awarded $6.6 million NIH grant to rapidly expand COVID-19 Test Capacity
September 02, 2020 11:05 ET | Aegis Sciences Corporation
NASHVILLE, Tenn., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Aegis Sciences Corporation, a leading healthcare company that provides clinically innovative medication compliance testing and consulting...
logo-dark.png
Aegis Sciences Corporation Announces National Launch of COVID-19 Antibody Testing Utilizing Convenient Dry Blood Spot Technology
August 31, 2020 10:30 ET | Aegis Sciences Corporation
NASHVILLE, Tenn., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Aegis Sciences Corporation, a leading healthcare company that provides clinically innovative medication compliance testing and consulting services...